Life Sciences

  • April 13, 2026

    Inventors Face Bayh-Dole Act Reporting Issues, GAO Says

    Universities and businesses that hold on to patent rights after receiving federal funds for developing the inventions have pointed to problems with the reporting requirements, according to the U.S. Government Accountability Office.

  • April 13, 2026

    Texas GLP-1 Compounder Caused Mom's Death, Family Says

    A Houston compounding pharmacy misled consumers by marketing its weight loss and diabetes drugs as safe and pharmaceutical-grade while selling contaminated medicines, a deceased Texas woman's family claims in a wrongful death lawsuit, alleging the drugs led to the woman's death. 

  • April 13, 2026

    11th Circ. Backs FDA's Ban Over Drug Tester's Conviction

    The Eleventh Circuit on Monday backed a U.S. Food and Drug Administration order barring a former pharmaceutical worker from future interaction with the agency after she was convicted of lying during an investigation of her company, rejecting her bid for judicial review of the decision.

  • April 13, 2026

    Chamber, Other Biz Groups Back Insulin Cos. At High Court

    The U.S. Chamber of Commerce and other business groups urged the U.S. Supreme Court to take up an appeal from Sanofi-Aventis, Eli Lilly, Novo Nordisk and AstraZeneca, arguing the Second Circuit's revival of an antitrust suit risks opening up liability just for trade group membership.

  • April 13, 2026

    Ex-Med Spa Workers Settle Conn. Poaching Claims

    A Connecticut medical spa has settled a state court lawsuit accusing two former employees of luring clients and a colleague to a similar facility less than six miles away, court records show.

  • April 10, 2026

    Medtronic Can't Ax $382M Trial Loss, Applied Medical Says

    Applied Medical Resources Corp. has urged a California federal court to reject Medtronic Inc.'s attempt to ditch its roughly $382 million antitrust trial loss, arguing that Medtronic is simply repeating "erroneous legal arguments this court already rejected."

  • April 10, 2026

    Chest Binders Become Latest Front In Anti-Trans Litigation

    Chest binders — medical devices that can be used by individuals experiencing gender dysphoria or who want a more gender-neutral alternative to bras — have emerged as the newest target in an unfolding regulatory and legal climate that transgender advocates describe as an overtly partisan political attack against a type of product that the U.S. Food and Drug Administration has deemed the least risky.

  • April 10, 2026

    Chinese Scholar Gets Time Served For Smuggling E. Coli DNA

    A Chinese postdoctoral research associate at Indiana University was sentenced to time served on Wednesday by an Indiana federal judge, spending more than four months in custody on smuggling charges for shipping an E. coli sample from China into the U.S. and lying about it when questioned by U.S. Customs and Border Protection agents. 

  • April 10, 2026

    NJ Justices Won't Review Beasley Allen's DQ From Talc Cases

    The New Jersey Supreme Court has declined to review a lower court's order booting the Beasley Allen Law Firm from multicounty litigation in the Garden State over Johnson & Johnson's talcum powder, according to an order made public Friday.

  • April 10, 2026

    Drugmakers Can Intervene In Texas, Fla. Abortion Drug Suit

    A federal judge Friday allowed abortion medication manufacturers GenBioPro Inc. and Danco Laboratories to intervene in litigation brought by the states of Texas and Florida seeking to undo a slew of federal regulations concerning the abortion drug mifepristone.

  • April 10, 2026

    Elevance Can't Nix Suit Over GLP-1 Coverage For Sleep Apnea

    An Indiana federal judge declined to toss a proposed class action claiming Elevance Health Inc. illegally denied coverage for a GLP-1 weight loss medication that was prescribed to treat sleep apnea, ruling that the insurance company is the right party to answer to the allegations at play.

  • April 10, 2026

    Taxation With Representation: Goodwin, CMS, Wilson Sonsini

    In this week's Taxation With Representation, Gilead Sciences Inc. acquires clinical-stage biotechnology company Tubulis GmbH, private equity firm Court Square Capital Partners closes a multibillion-dollar fund and Neurocrine Biosciences Inc. buys rare-disease drugmaker Soleno Therapeutics Inc.

  • April 10, 2026

    Ill. Jury Adds $17M Punitive Award To Baby Formula Verdict

    Illinois jurors on Friday slapped another $17 million in punitive damages atop the $53 million they awarded the previous afternoon to four mothers who accused Abbott Laboratories of selling preterm infant formula that contributed to a serious and often fatal gut condition their babies developed.

  • April 09, 2026

    Yale Medical School Can't Nix Fraudulent Insemination Suit

    Yale can't escape a negligence suit by onetime patients alleging its former fertility doctor secretly inseminated them with his own sperm, after a Connecticut judge said that a letter from an anonymous doctor, which is mandated by law to support their claims, met the statutory requirements.

  • April 09, 2026

    Irish Mallinckrodt Unit Stuck In Drug Price-Fixing Suit

    An Irish entity of drugmaker Mallinckrodt waited too long to seek dismissal of a price-fixing lawsuit brought by states based on a lack of personal jurisdiction or proper service, a Connecticut federal judge has ruled, finding that the company first raised that argument more than five years after the complaint was filed.

  • April 09, 2026

    Abbott Hit With $53M Verdict Over Baby Formula Harms

    A Cook County jury on Thursday awarded a total of $53 million in damages to four mothers claiming Abbott Laboratories' preterm baby formula contributed to their babies' development of a serious and often fatal gut condition, in the first of such claims to go to trial in Illinois.

  • April 09, 2026

    Split 4th Circ. Backs West Virginia Schoolchildren Vax Law

    A split Fourth Circuit panel struck down an order barring West Virginia from applying a compulsory vaccination law to a student whose parents alleged the law violates her religious rights, ruling the law serves the state's interest in reducing the spread of infectious diseases.

  • April 09, 2026

    Merck Beats 295 Zostavax Suits Over Missed Deadlines

    A Pennsylvania federal judge has tossed 295 cases against Merck & Co. Inc. in the multidistrict litigation alleging its Zostavax shingles vaccine caused the disease, with the court reasoning that the plaintiffs' inactivity doomed the cases.

  • April 09, 2026

    McKinsey Settles Liability For $125M In Purdue Ch. 11

    Consulting firm McKinsey & Co. has agreed to pay $125 million to former client Purdue Pharma LP to settle potential claims related to its work advising Purdue on the sale and marketing of opioids, tying up another loose end in the nearly seven-year-old Chapter 11 case.

  • April 09, 2026

    Nonprofit Insurer Wants To Seek AstraZeneca Claims Revival

    EmblemHealth asked a Massachusetts federal judge to let it seek First Circuit intervention against a decision that cut in half its proposed class action accusing AstraZeneca unit Alexion of using sham patents to protect blood disorder treatment Soliris from biosimilar rivals.

  • April 09, 2026

    Philly Injection Site Row Judge Rejects Nonprofit's 'Ploy'

    A Pennsylvania federal judge on Thursday called the addition of overdose prevention nonprofit Safehouse's president as a counterclaim plaintiff in the government's suit to stop it from launching a safe-injection site in Philadelphia a "ploy" to add another to the ranks of those claiming the government infringed the group's religious freedom.

  • April 09, 2026

    Abiomed Can't Escape Blood Pump Patent Case

    A Massachusetts federal judge has refused to let a Johnson & Johnson MedTech subsidiary dodge claims that it infringed a blood pump patent, the latest event in a wider legal battle launched against it by a unit of Swedish medical device company Getinge AB.

  • April 09, 2026

    Ecolab Says Personal Injury Law Firm Holding Back $148K

    Ecolab and its self-funded employee benefit plan have accused a North Carolina personal injury firm of withholding around $148,000 in settlement funds the food safety company says it's owed for covering a worker's medical bills after a car accident.

  • April 09, 2026

    Ex-Pharmacy Director Denies Using Trade Secrets At New Job

    A former director at a specialty infusion therapy pharmacy urged a New Jersey federal court to reject her former employer's bid to block her from working for a rival, arguing that her new job does not pose any threat of imminent harm to her former company.

  • April 09, 2026

    US Again Urges High Court To Back Drug Price Program

    The administration of President Donald Trump again urged the Supreme Court not to hear a challenge to the Medicare drug price negotiation program, arguing against a constitutional challenge brought by Boehringer Ingelheim that drug companies aren't forced to accept lower prices because they can choose not to participate. 

Expert Analysis

  • NYC Bar Opinion Warns Attys On Use Of AI Recording Tools

    Author Photo

    Attorneys who use artificial intelligence tools to record, transcribe and summarize conversations with clients should heed the New York City Bar Association’s recent opinion addressing the legal and ethical risks posed by such tools, and follow several best practices to avoid violating the Rules of Professional Conduct, say attorneys at Smith Gambrell.

  • Series

    The Biz Court Digest: Dispatches From Utah's Newest Court

    Author Photo

    While a robust body of law hasn't yet developed since the Utah Business and Chancery Court's founding in October 2024, the number of cases filed there has recently picked up, and its existence illustrates Utah's desire to be top of mind for businesses across the country, says Evan Strassberg at Michael Best.

  • Checking In On Biologics-Related Patent Review Trends

    Author Photo

    Comprehensive analysis of Patent Trial and Appeal Board data since the PTAB's creation indicates that while inter partes review and post-grant review are potent weapons for challenging biologics-related patents, recent policy changes may reduce their effectiveness, say attorneys at Steptoe.

  • 4 Quick Emotional Resets For Lawyers With Conflict Fatigue

    Author Photo

    Though the emotional wear and tear of legal work can trap attorneys in conflict fatigue — leaving them unable to shake off tense interactions or return to a calm baseline — simple therapeutic techniques for resetting the nervous system can help break the cycle, says Chantel Cohen at CWC Coaching & Therapy.

  • Rescheduling Cannabis Marks New Tax Era For Operators

    Author Photo

    As the attorney general takes steps to move cannabis from Schedule I to Schedule III of the Controlled Substances Act, operators and advisers should prepare by considering the significant changes this will bring from tax, state, industry and market perspectives, says Michael Harlow at CohnReznick.

  • Navigating Trade Secret Exceptions In Noncompete Bans

    Author Photo

    Recent and ongoing developments in the noncompete landscape, including a potential decision from the Tenth Circuit in Edwards Lifesciences v. Thompson, could offer tools for employers to bring noncompete agreements within trade secret exceptions amid an era of heightened employee mobility, say attorneys at Sullivan & Cromwell.

  • Series

    Playing Tennis Makes Me A Better Lawyer

    Author Photo

    An instinct to turn pain into purpose meant frequent trips to the tennis court, where learning to move ahead one point at a time was a lesson that also applied to the steep learning curve of patent prosecution law, says Daniel Henry at Marshall Gerstein.

  • Expect Major Shifts In Patent And Trademark Policy This Year

    Author Photo

    New leadership and initiatives promise to bring consequential changes to the U.S. Patent and Trademark Office's practices in 2026, likely favoring patent allowance and issuance, as well as streamlining trademark processes, say attorneys at Knobbe Martens.

  • Class Actions At The Circuit Courts: January Lessons

    Author Photo

    In this month's review of class action appeals, Mitchell Engel at Shook Hardy discusses five rulings from October and November, and identifies practice tips from cases involving consumer fraud, oil and gas leases, toxic torts, and wage and hour issues.

  • Series

    Judges On AI: How Judicial Use Informs Guardrails

    Author Photo

    U.S. Magistrate Judge Maritza Dominguez Braswell at the U.S. District Court for the District of Colorado discusses why having a sense of how generative AI tools behave, where they add value, where they introduce risk and how they are reshaping the practice of law is key for today's judges.

  • What US Cos. Must Know To Comply With Italy's AI Law

    Author Photo

    Italy's newly effective artificial intelligence law means U.S. companies operating in Italy or serving Italian customers must now meet EU AI Act obligations as well as Italy-specific requirements, including immediately enforceable criminal penalties, designated national authorities and sector-specific mandates, say attorneys at Portolano Cavallo.

  • Ag Bill Wording Presents Existential Threat To Hemp Industry

    Author Photo

    A proposal in the agriculture appropriations bill for fiscal year 2026, which excludes almost everything synthesized from cannabis from the legal definition of “hemp,” would have catastrophic consequences for thousands of farmers, medical researchers and businesses by banning everything from intoxicating delta-9 THC products to topical CBD creams, says Alissa "Ali" Jubelirer at Benesch.

  • Series

    Adapting To Private Practice: 5 Tips From Ex-SEC Unit Chief

    Author Photo

    My move to private practice has reaffirmed my belief in the value of adaptability, collaboration and strategic thinking — qualities that are essential not only for successful client outcomes, but also for sustained professional satisfaction, says Dabney O’Riordan at Fried Frank.

  • 5 Drug Pricing Policy Developments To Watch In 2026

    Author Photo

    2026 may prove to be a critical year for drug pricing in the U.S., with potential major shifts including several legislative initiatives moving forward after being in the works for years, and more experimentation on the horizon concerning GLP-1s and Section 340B pricing, say attorneys at Manatt.

  • Patent Applicants Must Get Biologics Enablement Right

    Author Photo

    As artificial intelligence increasingly becomes a core driver in drug discovery, it is critical for drug companies to adapt their drafting strategies to the unique features of AI-generated inventions, and to pay particularly close attention to enablement standards, says Sanandan Malhotra at Novo Nordisk.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.